147 related articles for article (PubMed ID: 38362852)
1. The heterogeneous cancer phenotype of individuals with biallelic germline pathogenic variants in CHEK2.
Hinić S; Cybulski C; Van der Post RS; Vos JR; Schuurs-Hoeijmakers J; Brugnoletti F; Koene S; Vreede L; van Zelst-Stams WAG; Kets CM; Haadsma M; Spruijt L; Wevers MR; Evans DG; Wimmer K; Schnaiter S; Volk AE; Möllring A; de Putter R; Soikkonen L; Kahre T; Tooming M; de Jong MM; Vaz F; Mensenkamp AR; Genuardi M; Lubinski J; Ligtenberg M; Hoogerbrugge N; de Voer RM
Genet Med; 2024 May; 26(5):101101. PubMed ID: 38362852
[TBL] [Abstract][Full Text] [Related]
2. High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.
Rainville I; Hatcher S; Rosenthal E; Larson K; Bernhisel R; Meek S; Gorringe H; Mundt E; Manley S
Breast Cancer Res Treat; 2020 Apr; 180(2):503-509. PubMed ID: 31993860
[TBL] [Abstract][Full Text] [Related]
3.
Brock P; Liynarachchi S; Nieminen TT; Chan C; Kohlmann W; Stout LA; Yao S; La Greca A; Jensen KE; Kolesar JM; Salhia B; Gulhati P; Hicks JK; Ringel MD
Thyroid; 2024 Apr; 34(4):477-483. PubMed ID: 38279823
[No Abstract] [Full Text] [Related]
4. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
5. Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care-Checking CHEK2.
Bychkovsky BL; Agaoglu NB; Horton C; Zhou J; Yussuf A; Hemyari P; Richardson ME; Young C; LaDuca H; McGuinness DL; Scheib R; Garber JE; Rana HQ
JAMA Oncol; 2022 Nov; 8(11):1598-1606. PubMed ID: 36136322
[TBL] [Abstract][Full Text] [Related]
6. Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors.
AlDubayan SH; Pyle LC; Gamulin M; Kulis T; Moore ND; Taylor-Weiner A; Hamid AA; Reardon B; Wubbenhorst B; Godse R; Vaughn DJ; Jacobs LA; Meien S; Grgic M; Kastelan Z; Markt SC; Damrauer SM; Rader DJ; Kember RL; Loud JT; Kanetsky PA; Greene MH; Sweeney CJ; Kubisch C; Nathanson KL; Van Allen EM; Stewart DR; Lessel D;
JAMA Oncol; 2019 Apr; 5(4):514-522. PubMed ID: 30676620
[TBL] [Abstract][Full Text] [Related]
7. Spectrum and frequency of CHEK2 variants in breast cancer affected and general population in the Baltic states region, initial results and literature review.
Pavlovica K; Irmejs A; Noukas M; Palover M; Kals M; Tonisson N; Metspalu A; Gronwald J; Lubinski J; Murmane D; Kalnina A; Loza P; Maksimenko J; Trofimovics G; Subatniece S; Daneberga Z; Miklasevics E; Gardovskis J
Eur J Med Genet; 2022 May; 65(5):104477. PubMed ID: 35314380
[TBL] [Abstract][Full Text] [Related]
8. The genomic landscape of breast- and non-breast cancers from individuals with germline CHEK2-deficiency.
Hinić S; van der Post RS; Vreede L; Schuurs-Hoeijmakers J; Koene S; Jansen EAM; Bervoets-Metge F; Mensenkamp AR; Hoogerbrugge N; Ligtenberg MJL; de Voer RM
JNCI Cancer Spectr; 2024 Jun; ():. PubMed ID: 38848470
[TBL] [Abstract][Full Text] [Related]
9. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
[TBL] [Abstract][Full Text] [Related]
10. Differences in cancer prevalence among CHEK2 carriers identified via multi-gene panel testing.
Sutcliffe EG; Stettner AR; Miller SA; Solomon SR; Marshall ML; Roberts ME; Susswein LR; Arvai KJ; Klein RT; Murphy PD; Hruska KS
Cancer Genet; 2020 Aug; 246-247():12-17. PubMed ID: 32805687
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants.
Schwartz CJ; Khorsandi N; Blanco A; Mukhtar RA; Chen YY; Krings G
Breast Cancer Res Treat; 2024 Feb; 204(1):171-179. PubMed ID: 38091153
[TBL] [Abstract][Full Text] [Related]
12. Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies.
Stubbins RJ; Korotev S; Godley LA
Curr Hematol Malig Rep; 2022 Aug; 17(4):94-104. PubMed ID: 35674998
[TBL] [Abstract][Full Text] [Related]
13. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
[TBL] [Abstract][Full Text] [Related]
14. A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients.
Wendt C; Muranen TA; Mielikäinen L; Thutkawkorapin J; Blomqvist C; Jiao X; Ehrencrona H; Tham E; Arver B; Melin B; Kuchinskaya E; Stenmark Askmalm M; Paulsson-Karlsson Y; Einbeigi Z; von Wachenfeldt Väppling A; Kalso E; Tasmuth T; Kallioniemi A; Aittomäki K; Nevanlinna H; Borg Å; Lindblom A
Sci Rep; 2021 Jul; 11(1):14763. PubMed ID: 34285278
[TBL] [Abstract][Full Text] [Related]
15.
Stolarova L; Kleiblova P; Janatova M; Soukupova J; Zemankova P; Macurek L; Kleibl Z
Cells; 2020 Dec; 9(12):. PubMed ID: 33322746
[TBL] [Abstract][Full Text] [Related]
16. The CHK2 kinase is recurrently mutated and functionally impaired in the germline of pediatric cancer patients.
Wagener R; Walter C; Auer F; Alzoubi D; Hauer J; Fischer U; Varghese J; Dugas M; Borkhardt A; Brozou T
Int J Cancer; 2023 Apr; 152(7):1388-1398. PubMed ID: 36468172
[TBL] [Abstract][Full Text] [Related]
17. Small fraction of testicular cancer cases may be causatively related to CHEK2 inactivating germ-line mutations: evidence for somatic loss of the remaining CHEK2 allele in the tumor tissue.
Ni VI; Ivantsov AO; Kotkova MA; Baskina SV; Ponomareva EV; Orlova RV; Topuzov EE; Kryukov KK; Shelekhova KV; Aleksakhina SN; Sokolenko AP; Imyanitov EN
Fam Cancer; 2021 Jan; 20(1):49-53. PubMed ID: 32451744
[TBL] [Abstract][Full Text] [Related]
18. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.
Bell DW; Kim SH; Godwin AK; Schiripo TA; Harris PL; Haserlat SM; Wahrer DC; Haiman CA; Daly MB; Niendorf KB; Smith MR; Sgroi DC; Garber JE; Olopade OI; Le Marchand L; Henderson BE; Altshuler D; Haber DA; Freedman ML
Int J Cancer; 2007 Dec; 121(12):2661-7. PubMed ID: 17721994
[TBL] [Abstract][Full Text] [Related]
19. Germline drivers of gynecologic carcinosarcomas.
Sia TY; Gordhandas SB; Birsoy O; Kemel Y; Maio A; Salo-Mullen E; Sheehan M; Hensley ML; Rubinstein M; Makker V; Grisham RN; O'Cearbhaill RE; Roche KL; Mueller JJ; Leitao MM; Sonoda Y; Chi DS; Abu-Rustum NR; Berger MF; Ellenson LH; Latham A; Stadler Z; Offit K; Aghajanian C; Weigelt B; Mandelker D; Liu YL
Gynecol Oncol; 2023 Jul; 174():34-41. PubMed ID: 37149903
[TBL] [Abstract][Full Text] [Related]
20. Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk.
Boonen RACM; Wiegant WW; Celosse N; Vroling B; Heijl S; Kote-Jarai Z; Mijuskovic M; Cristea S; Solleveld-Westerink N; van Wezel T; Beerenwinkel N; Eeles R; Devilee P; Vreeswijk MPG; Marra G; van Attikum H
Cancer Res; 2022 Feb; 82(4):615-631. PubMed ID: 34903604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
